European Immunization Week 2018- Statement of Guido Rasi, Executive Director, European Medicines Agency

Posted on: 26/04/2018 - 13:27

Vaccines matter for each of us: yearly, they prevent 2.7 million people from contracting measles, one million from getting whooping cough and two million babies from getting tetanus. They eradicated smallpox. They stopped polio, a dreadful disease affecting millions of children, in almost all... more

Field of Interest: European Union Medical News
Type: News Feed

Opinion/decision on a Paediatric investigation plan (PIP): Ocrevus, ocrelizumab, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Neurology, PIP number: EMA/PE/0000237224

Submitted by Anonymous (not verified) on 3 July 2026 - 11:40

Opinion/decision on a Paediatric investigation plan (PIP): Ocrevus, ocrelizumab, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Neurology, PIP number: EMA/PE/0000237224

Opinion/decision on a Paediatric investigation plan (PIP): Edarbi, azilsartan medoxomil, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Vascular disorders, PIP number: EMA/PE/0000237559

Submitted by Anonymous (not verified) on 3 July 2026 - 11:00

Opinion/decision on a Paediatric investigation plan (PIP): Edarbi, azilsartan medoxomil, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Vascular disorders, PIP number: EMA/PE/0000237559

Opinion/decision on a Paediatric investigation plan (PIP): Kerendia, finerenone, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Renal and urinary disorders, PIP number: EMA/PE/0000235999

Submitted by Anonymous (not verified) on 3 July 2026 - 11:00

Opinion/decision on a Paediatric investigation plan (PIP): Kerendia, finerenone, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Renal and urinary disorders, PIP number: EMA/PE/0000235999

Workshop on the use of external controls for evidence generation in regulatory decision-making, Online, European Medicines Agency, Amsterdam, the Netherlands, from 3 November 2025, 10:00 (CET) to 3 November 2025, 17:30 (CET)

Submitted by Anonymous (not verified) on 3 July 2026 - 10:22

Workshop on the use of external controls for evidence generation in regulatory decision-making, Online, European Medicines Agency, Amsterdam, the Netherlands, from 3 November 2025, 10:00 (CET) to 3 November 2025, 17:30 (CET)

Newsletters

Stay informed on our latest news!

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Latest Newsletters

More
randomness